THERAPEUTICS OF MULTIPLE-SCLEROSIS

被引:14
作者
NOSEWORTHY, JH
机构
[1] Department of Neurology, Mayo Clinic, Rochester
关键词
MULTIPLE SCLEROSIS; RANDOMIZED TRIALS; CLINICAL TRIALS; DOUBLE-BLIND METHOD;
D O I
10.1097/00002826-199102000-00004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of MS is far from satisfactory. Patients and their families should be provided with a chance to learn about the illness and their emotional and social needs should be addressed by knowledgeeable and supportive staff e.g., neurologists, psychologists, psychiatrists, social workers, physiotherapists, occupational therapists, and dieticians). Patients who are in remission should be encouraged to enjoy an active life, and to seek prompt medical attention and rest if they develop symptoms of an infection. They should contact their physician at times of apparent disease activity so that intercurrent infections can be properly identified and treated and so that ACTH or corticosteroids can be started if warranted. Currently, there appears to be little evidence that immunosuppressive drugs significantly affect the natural history of the disease. These agents should be administered only in the setting of controlled clinical trials by physicians experienced with their use. Whenever possible, patients with progressive disease should be offered a chance to participate in controlled clinical trials. Failing this, corticosteroids can be tried and repeated in patients who seem to benefit but prolonged steroid use should be avoided. Most of the complications of MS can be managed with some success. While we await a better understanding of the factors that contribute to disease activity, both definitive treatment and treatment of complications will continue to be directed by the results of carefully designed and properly controlled, randomized clinical trials.
引用
收藏
页码:49 / 61
页数:13
相关论文
共 74 条
[1]  
[Anonymous], 1990, ANN NEUROL, V27, P591
[2]  
BASS B, 1990, Neurology, V40, P261
[3]   TIZANIDINE VERSUS BACLOFEN IN THE TREATMENT OF SPASTICITY IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
BASS, B ;
WEINSHENKER, B ;
RICE, GPA ;
NOSEWORTHY, JH ;
CAMERON, MGP ;
HADER, W ;
BOUCHARD, S ;
EBERS, GC .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1988, 15 (01) :15-19
[4]   A DOUBLE-BLIND CONTROLLED TRIAL OF LONG-CHAIN N-3 POLY-UNSATURATED FATTY-ACIDS IN THE TREATMENT OF MULTIPLE-SCLEROSIS [J].
BATES, D ;
CARTLIDGE, NEF ;
FRENCH, JM ;
JACKSON, MJ ;
NIGHTINGALE, S ;
SHAW, DA ;
SMITH, S ;
WOO, E ;
HAWKINS, SA ;
MILLAR, JHD ;
BELIN, J ;
CONROY, DM ;
GILL, SK ;
SIDEY, M ;
SMITH, AD ;
THOMPSON, RHS ;
ZILKHA, K ;
GALE, M ;
SINCLAIR, HM .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1989, 52 (01) :18-22
[5]   MULTIPLE-SCLEROSIS BLADDER - STUDIES AND CARE [J].
BLAIVAS, JG ;
HOLLAND, NJ ;
GIESSER, B ;
LAROCCA, N ;
MADONNA, M ;
SCHEINBERG, L .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1984, 436 (DEC) :328-346
[6]   A PILOT TRIAL OF COP-1 IN EXACERBATING REMITTING MULTIPLE-SCLEROSIS [J].
BORNSTEIN, MB ;
MILLER, A ;
SLAGLE, S ;
WEITZMAN, M ;
CRYSTAL, H ;
DREXLER, E ;
KEILSON, M ;
MERRIAM, A ;
WASSERTHEILSMOLLER, S ;
SPADA, V ;
WEISS, W ;
ARNON, R ;
JACOBSOHN, I ;
TEITELBAUM, D ;
SELA, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (07) :408-414
[7]   PERCUTANEOUS TRIGEMINAL RHIZOTOMY - TREATMENT OF TRIGEMINAL NEURALGIA SECONDARY TO MULTIPLE-SCLEROSIS [J].
BRETT, DC ;
FERGUSON, GG ;
EBERS, GC ;
PATY, DW .
ARCHIVES OF NEUROLOGY, 1982, 39 (04) :219-221
[8]  
CAMENGA DL, 1986, ARCH NEUROL-CHICAGO, V143, P1239
[9]  
CARTER JL, 1988, NEUROLOGY, V38, P9
[10]   AMANTADINE TREATMENT OF FATIGUE ASSOCIATED WITH MULTIPLE-SCLEROSIS [J].
COHEN, RA ;
FISHER, M .
ARCHIVES OF NEUROLOGY, 1989, 46 (06) :676-680